Literature DB >> 17192765

Coenzyme Q10: a review of its promise as a neuroprotectant.

A Joyce Young1, Stephanie Johnson, David C Steffens, P Murali Doraiswamy.   

Abstract

Coenzyme Q10 (CoQ10) is a powerful antioxidant that buffers the potential adverse consequences of free radicals produced during oxidative phosphorylation in the inner mitochondrial membrane. Oxidative stress, resulting in glutathione loss and oxidative DNA and protein damage, has been implicated in many neurodegenerative disorders, including Alzheimer's disease, Parkinson's disease, and Huntington's disease. Experimental studies in animal models suggest that CoQ10 may protect against neuronal damage that is produced by ischemia, atherosclerosis and toxic injury. Though most have tended to be pilot studies, there are published preliminary clinical trials showing that CoQ10 may offer promise in many brain disorders. For example, a 16-month randomized, placebo-controlled pilot trial in 80 subjects with mild Parkinson's disease found significant benefits for oral CoQ10 1,200 mg/day to slow functional deterioration. However, to date, there are no published clinical trials of CoQ10 in Alzheimer's disease. Available data suggests that oral CoQ10 seems to be relatively safe and tolerated across the range of 300-2,400 mg/day. Randomized controlled trials are warranted to confirm CoQ10's safety and promise as a clinically effective neuroprotectant.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17192765     DOI: 10.1017/s1092852900020538

Source DB:  PubMed          Journal:  CNS Spectr        ISSN: 1092-8529            Impact factor:   3.790


  25 in total

Review 1.  Therapeutic Strategies and Nano-Drug Delivery Applications in Management of Aging Alzheimer's Disease.

Authors:  Thuy Trang Nguyen; Tuong Kha Vo; Giau Van Vo
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

Review 2.  Potential future neuroprotective therapies for neurodegenerative disorders and stroke.

Authors:  Rawan Tarawneh; James E Galvin
Journal:  Clin Geriatr Med       Date:  2010-02       Impact factor: 3.076

3.  Progress in the development of new drugs in Alzheimer's disease.

Authors:  Antoine Piau; F Nourhashémi; C Hein; C Caillaud; B Vellas
Journal:  J Nutr Health Aging       Date:  2011-01       Impact factor: 4.075

Review 4.  Bioenergetic medicine.

Authors:  Russell H Swerdlow
Journal:  Br J Pharmacol       Date:  2014-04       Impact factor: 8.739

5.  Coenzyme Q10 reduces beta-amyloid plaque in an APP/PS1 transgenic mouse model of Alzheimer's disease.

Authors:  Xifei Yang; George Dai; Geng Li; Edward S Yang
Journal:  J Mol Neurosci       Date:  2009-10-16       Impact factor: 3.444

6.  Paraquat induces oxidative stress, neuronal loss in substantia nigra region and parkinsonism in adult rats: neuroprotection and amelioration of symptoms by water-soluble formulation of coenzyme Q10.

Authors:  Mallika Somayajulu-Niţu; Jagdeep K Sandhu; Jerome Cohen; Marianna Sikorska; T S Sridhar; Anca Matei; Henryk Borowy-Borowski; Siyaram Pandey
Journal:  BMC Neurosci       Date:  2009-07-27       Impact factor: 3.288

7.  Consumption of pasteurized human lysozyme transgenic goats' milk alters serum metabolite profile in young pigs.

Authors:  Dottie R Brundige; Elizabeth A Maga; Kirk C Klasing; James D Murray
Journal:  Transgenic Res       Date:  2009-10-22       Impact factor: 2.788

8.  The therapeutic potential of LRRK2 and alpha-synuclein in Parkinson's disease.

Authors:  Saurabh Sen; Andrew B West
Journal:  Antioxid Redox Signal       Date:  2009-09       Impact factor: 8.401

9.  Coenzyme q10 ameliorates neurodegeneration, mossy fiber sprouting, and oxidative stress in intrahippocampal kainate model of temporal lobe epilepsy in rat.

Authors:  Tourandokht Baluchnejadmojarad; Mehrdad Roghani
Journal:  J Mol Neurosci       Date:  2012-09-25       Impact factor: 3.444

10.  Potent induction of total cellular GSH and NQO1 as well as mitochondrial GSH by 3H-1,2-dithiole-3-thione in SH-SY5Y neuroblastoma cells and primary human neurons: protection against neurocytotoxicity elicited by dopamine, 6-hydroxydopamine, 4-hydroxy-2-nonenal, or hydrogen peroxide.

Authors:  Zhenquan Jia; Hong Zhu; Hara P Misra; Yunbo Li
Journal:  Brain Res       Date:  2008-01-03       Impact factor: 3.252

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.